{"id":"placebo-fluoxetine","safety":{"commonSideEffects":[{"rate":"20-25","effect":"Nausea"},{"rate":"15-20","effect":"Headache"},{"rate":"10-15","effect":"Insomnia"},{"rate":"10-15","effect":"Somnolence"},{"rate":"10-15","effect":"Sexual dysfunction"},{"rate":"10-12","effect":"Diarrhea"},{"rate":"5-10","effect":"Tremor"},{"rate":"5-10","effect":"Anxiety"}]},"_chembl":{"chemblId":"CHEMBL1201082","moleculeType":"Small molecule","molecularWeight":"345.79"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that blocks the reuptake transporter for serotonin, prolonging serotonin's presence in the synaptic cleft. This enhanced serotonergic neurotransmission is thought to alleviate symptoms of depression and anxiety. The placebo component in this formulation serves as a control or comparative element in clinical research.","oneSentence":"Fluoxetine selectively inhibits serotonin reuptake in the brain, increasing serotonin availability at synapses to improve mood and reduce depressive symptoms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:41.767Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Obsessive-compulsive disorder"},{"name":"Panic disorder"},{"name":"Bulimia nervosa"},{"name":"Premenstrual dysphoric disorder"}]},"trialDetails":[{"nctId":"NCT06898606","phase":"PHASE1, PHASE2","title":"Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression","status":"RECRUITING","sponsor":"Federal University of Latin American Integration","startDate":"2024-09-05","conditions":"Depressive Disorder","enrollment":24},{"nctId":"NCT07174947","phase":"PHASE2","title":"SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10-01","conditions":"Hepatobiliary Malignancy, Fluoxetine, Anxiety Disorders","enrollment":240},{"nctId":"NCT07456501","phase":"NA","title":"Fluoxetine and Understanding Social Experiences","status":"NOT_YET_RECRUITING","sponsor":"University of Oxford","startDate":"2026-03","conditions":"Depression in Adolescence, Antidepressant Activity in Healthy Volunteers, Healthy Adult Participants","enrollment":80},{"nctId":"NCT07424781","phase":"NA","title":"Fluoxetine on Emotional Experience (FLEX) Study","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2025-10-01","conditions":"Depression - Major Depressive Disorder, Irritability, Depression","enrollment":80},{"nctId":"NCT07007221","phase":"PHASE2","title":"Clinical Trials to Evaluate Metformin to Treat Depression in People Living With HIV","status":"NOT_YET_RECRUITING","sponsor":"University of Minnesota","startDate":"2026-07-01","conditions":"Depression, Hiv","enrollment":600},{"nctId":"NCT07203144","phase":"PHASE2","title":"Selenium Supplementation for Improving Depression in Children and Adolescents: Efficacy and Mechanistic Study","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2025-12-31","conditions":"Depression - Major Depressive Disorder","enrollment":172},{"nctId":"NCT03466346","phase":"NA","title":"SMART-DAPPER: Leveraging the Depression And Primary-care Partnership for Effectiveness-implementation Research Project","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2020-08-31","conditions":"Depression, Unipolar, Posttraumatic Stress Disorder, Trauma","enrollment":2162},{"nctId":"NCT07239011","phase":"PHASE1, PHASE2","title":"Dapagliflozin in Depression","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-11-01","conditions":"Depression","enrollment":60},{"nctId":"NCT01672255","phase":"EARLY_PHASE1","title":"Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM)","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2012-10","conditions":"Type 1 Diabetes, Hypoglycemia Associated Autonomic Failure","enrollment":64},{"nctId":"NCT03228732","phase":"EARLY_PHASE1","title":"The Effects of Fluoxetine and/or DHEA","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2017-12-19","conditions":"Type 1 Diabetes Mellitus","enrollment":60},{"nctId":"NCT02751632","phase":"PHASE3","title":"The Staged Treatment in Early Psychosis Study","status":"COMPLETED","sponsor":"Orygen","startDate":"2016-04","conditions":"Psychotic Disorders, Personality Disorders, Clinical High Risk","enrollment":342},{"nctId":"NCT05948553","phase":"PHASE2","title":"Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine","status":"RECRUITING","sponsor":"Global Coalition for Adaptive Research","startDate":"2023-11-02","conditions":"Post Traumatic Stress Disorder","enrollment":200},{"nctId":"NCT05422612","phase":"PHASE2","title":"Department of Defense PTSD Adaptive Platform Trial - Master Protocol","status":"RECRUITING","sponsor":"Global Coalition for Adaptive Research","startDate":"2023-11-02","conditions":"Post Traumatic Stress Disorder","enrollment":800},{"nctId":"NCT06591091","phase":"PHASE2","title":"Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2025-09","conditions":"Depression","enrollment":80},{"nctId":"NCT04131829","phase":"PHASE1, PHASE2","title":"Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD","status":"RECRUITING","sponsor":"Yale University","startDate":"2019-10-14","conditions":"Obsessive-Compulsive Disorder","enrollment":100},{"nctId":"NCT07120880","phase":"PHASE3","title":"Efficacy of Chronotherapeutic Combination for Major Depressive Episode With Insomnia","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-09","conditions":"Major Depressive Disorder (MDD) With Insomnia","enrollment":184},{"nctId":"NCT06506136","phase":"PHASE1, PHASE2","title":"Evaluation of Fluoxetine for Refractory Constipation With Somatic Symptom Disorder Features","status":"NOT_YET_RECRUITING","sponsor":"Zhifeng Zhao, PhD","startDate":"2025-09-01","conditions":"Refractory Constipation, Somatic Symptom Disorder (DSM-5), Functional Constipation (FC)","enrollment":194},{"nctId":"NCT03826875","phase":"PHASE2","title":"Poststroke Depression in Hemorrhagic Stroke","status":"COMPLETED","sponsor":"University of Washington","startDate":"2019-03-01","conditions":"Stroke Hemorrhagic, Depression","enrollment":8},{"nctId":"NCT05030623","phase":"PHASE1, PHASE2","title":"The Phosphodiesterase Inhibitor Tadalafil as an Adjunct to Antidepressants in Major Depressive Disorder Patients","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2021-08-01","conditions":"Major Depressive Disorder","enrollment":""},{"nctId":"NCT06341127","phase":"NA","title":"Fluoxetine in KCNC1-related Disorder","status":"COMPLETED","sponsor":"Holland Bloorview Kids Rehabilitation Hospital","startDate":"2024-01-17","conditions":"KCNC1 Related Disorder, Genetic Disease, Rare Diseases","enrollment":1},{"nctId":"NCT03321526","phase":"PHASE2","title":"A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-12-12","conditions":"Depressive Disorder, Major","enrollment":107},{"nctId":"NCT04951609","phase":"PHASE1","title":"A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-09-02","conditions":"Depressive Disorder, Major","enrollment":31},{"nctId":"NCT06046859","phase":"PHASE4","title":"Can Immediate Post-injury Fluoxetine Improve the Recovery Trajectories of Victims in Bodily Trauma?","status":"RECRUITING","sponsor":"University of Florida","startDate":"2024-03-01","conditions":"Musculoskeletal Injury","enrollment":200},{"nctId":"NCT06860958","phase":"PHASE3","title":"Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-03-01","conditions":"Depressive Disorder, Major","enrollment":60},{"nctId":"NCT04727424","phase":"PHASE3","title":"Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms","status":"RECRUITING","sponsor":"Cardresearch","startDate":"2021-01-19","conditions":"Covid19, SARS-Associated Coronavirus","enrollment":7819},{"nctId":"NCT00533117","phase":"PHASE4","title":"Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2001-03","conditions":"Borderline Personality Disorder","enrollment":91},{"nctId":"NCT05431413","phase":"PHASE2","title":"Rapid Improvement of Depression of Fluoxetine Combined With ATP","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2020-01-07","conditions":"Depression","enrollment":195},{"nctId":"NCT03538691","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-07-13","conditions":"Major Depressive Disorder","enrollment":1149},{"nctId":"NCT02767999","phase":"PHASE4","title":"Serotonin Selective Reuptake Inhibitor (SSRI) Effects on Cerebral Connectivity in Acute Ischemic Stroke","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2017-02-27","conditions":"Stroke","enrollment":25},{"nctId":"NCT02058693","phase":"PHASE4","title":"Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2010-12","conditions":"Major Depressive Disorder","enrollment":41},{"nctId":"NCT05850572","phase":"NA","title":"A Study of the Efficacy of Fecal Microbiota Transplantation(FMT) in the Treatment of Depression","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2023-07","conditions":"Depression","enrollment":100},{"nctId":"NCT05789186","phase":"EARLY_PHASE1","title":"Clinical Study of Cang Ai Volatile Oil (CAVO) on Mild to Moderate Depression in Children and Adolescents","status":"UNKNOWN","sponsor":"Chen Qian","startDate":"2023-05-01","conditions":"Depression","enrollment":108},{"nctId":"NCT05283954","phase":"PHASE2, PHASE3","title":"Use of a Combined Regimen of Fluoxetine, Prednisolone and Ivermectin in the Treatment of Mild COVID-19 to Prevent Disease Progression Progression in Papua New Guinea","status":"WITHDRAWN","sponsor":"Oriol Mitja","startDate":"2022-05-01","conditions":"SARS-CoV2 Infection, COVID-19","enrollment":""},{"nctId":"NCT03448159","phase":"PHASE2","title":"Fluoxetine Opens Window to Improve Motor Recovery After Stroke","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2019-01-01","conditions":"Stroke, Cerebrovascular Accident, Cerebral Infarction","enrollment":52},{"nctId":"NCT02709655","phase":"PHASE3","title":"Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2016-05-18","conditions":"Depressive Disorder, Major","enrollment":683},{"nctId":"NCT05378711","phase":"PHASE2","title":"Evaluating the Results of Physician and Parent Decisions to Treat Selective Mutism With Fluoxetine","status":"COMPLETED","sponsor":"Michigan State University","startDate":"2014-01-01","conditions":"Selective Mutism, Social Anxiety","enrollment":6},{"nctId":"NCT03569475","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder","status":"COMPLETED","sponsor":"Allergan","startDate":"2018-07-06","conditions":"Major Depressive Disorder","enrollment":501},{"nctId":"NCT02737930","phase":"PHASE2","title":"Fluoxetine for Visual Recovery After Ischemic Stroke","status":"TERMINATED","sponsor":"Bogachan Sahin","startDate":"2016-05","conditions":"Acute Stroke, Visual Field Loss","enrollment":17},{"nctId":"NCT04780152","phase":"PHASE2, PHASE3","title":"TDCS in Pediatric and Teenage Patients With Major Depressive Disorder During COVID-19 Pandemic","status":"UNKNOWN","sponsor":"El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez","startDate":"2021-10","conditions":"Major Depressive Disorder","enrollment":172},{"nctId":"NCT00078754","phase":"PHASE2","title":"A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive Disorder","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2003-05","conditions":"Intermittent Explosive Disorder","enrollment":90},{"nctId":"NCT02472613","phase":"NA","title":"Acupuncture for Ischemic Post-stroke Depression","status":"COMPLETED","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2016-05","conditions":"Post-stroke Depression","enrollment":208},{"nctId":"NCT02208466","phase":"PHASE2","title":"Effects rTMS Combined With Fluoxetine on Motor Recovery in Stroke Patients","status":"COMPLETED","sponsor":"Spaulding Rehabilitation Hospital","startDate":"2014-09","conditions":"Stroke, Motor Function","enrollment":44},{"nctId":"NCT04570449","phase":"EARLY_PHASE1","title":"Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)","status":"WITHDRAWN","sponsor":"Milton S. Hershey Medical Center","startDate":"2020-11","conditions":"Covid19","enrollment":""},{"nctId":"NCT04676139","phase":"PHASE3","title":"The Safety and Efficacy of Fluoxetine for Refractory Primary Mono-symptomatic Nocturnal Enuresis in Children","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2020-07-01","conditions":"Nocturnal Enuresis","enrollment":100},{"nctId":"NCT02427334","phase":"PHASE3","title":"Dienogest Versus Luteal Phase Fluoxetine in the Management of Premenstrual Syndrome","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2015-04","conditions":"Premenstrual Syndrome","enrollment":210},{"nctId":"NCT00961961","phase":"PHASE4","title":"Prevention of Relapse & Recurrence of Bipolar Depression","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2009-07-01","conditions":"Bipolar Disorder","enrollment":177},{"nctId":"NCT02431806","phase":"PHASE3","title":"Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2015-06-23","conditions":"Major Depressive Disorder","enrollment":552},{"nctId":"NCT02683213","phase":"PHASE3","title":"Efficacy of Fluoxetine - a Trial in Stroke","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2014-10-20","conditions":"Stroke","enrollment":1500},{"nctId":"NCT02709746","phase":"PHASE3","title":"Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2016-05","conditions":"Depressive Disorder, Major","enrollment":784},{"nctId":"NCT04088448","phase":"PHASE1, PHASE2","title":"The Antidiabetic Metformin as a Novel Adjunct to Antidepressants in Major Depressive Disorder Patients","status":"COMPLETED","sponsor":"Sadat City University","startDate":"2017-01-01","conditions":"Major Depressive Disorder","enrollment":80},{"nctId":"NCT02929667","phase":"PHASE2","title":"Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI","status":"COMPLETED","sponsor":"Rup Kamal Sainju","startDate":"2017-02-16","conditions":"Epilepsy, SUDEP","enrollment":30},{"nctId":"NCT01910259","phase":"PHASE2","title":"MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial","status":"COMPLETED","sponsor":"University College, London","startDate":"2014-12-18","conditions":"Secondary Progressive Multiple Sclerosis","enrollment":445},{"nctId":"NCT00986310","phase":"NA","title":"Efficacy of Fluoxetine in Reducing Ictal Hypoventilation in Patients With Partial Epilepsy","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2009-08","conditions":"Uncontrolled Partial Epilepsy, Ictal Hypoventilation","enrollment":2},{"nctId":"NCT01687478","phase":"PHASE3","title":"A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2012-09","conditions":"Treatment Resistant Depression","enrollment":176},{"nctId":"NCT02372799","phase":"PHASE3","title":"Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2015-02-28","conditions":"Major Depressive Disorder","enrollment":473},{"nctId":"NCT01715805","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2012-11-15","conditions":"Major Depressive Disorder","enrollment":1022},{"nctId":"NCT00296725","phase":"PHASE1, PHASE2","title":"Dichotic Listening as a Predictor of Medication Response in Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"1994-04","conditions":"Major Depression, Dysthymia, Depressive Disorder Not Otherwise Specified","enrollment":25},{"nctId":"NCT01372150","phase":"PHASE3","title":"A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-11-17","conditions":"Major Depressive Disorder","enrollment":340},{"nctId":"NCT00578669","phase":"PHASE3","title":"Sequential Use of Fluoxetine for Smokers With Elevated Depressive Symptoms","status":"COMPLETED","sponsor":"Butler Hospital","startDate":"2008-04","conditions":"Major Depressive Disorder, Nicotine Dependence, Depression","enrollment":206},{"nctId":"NCT01615055","phase":"EARLY_PHASE1","title":"Fluoxetine Prevention Trial","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2018-06","conditions":"Cognitive Dysfunction","enrollment":""},{"nctId":"NCT00247624","phase":"PHASE4","title":"Improving Sleep and Psychological Functioning in People With Depression and Insomnia","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2005-10","conditions":"Sleep Initiation and Maintenance Disorders, Depression","enrollment":60},{"nctId":"NCT01469377","phase":"PHASE2","title":"Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2011-12-15","conditions":"Major Depressive Disorder","enrollment":819},{"nctId":"NCT00245635","phase":"PHASE4","title":"Fluoxetine in Pediatric Body Dysmorphic Disorder","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2004-11","conditions":"Body Dysmorphic Disorder","enrollment":43},{"nctId":"NCT01714310","phase":"PHASE2","title":"Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2013-01","conditions":"Severe Mood Dysregulation","enrollment":34},{"nctId":"NCT03436173","phase":"NA","title":"OxSYPan: Oxford Study With Young People on Antidepressants","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2012-05-23","conditions":"Depression","enrollment":32},{"nctId":"NCT00288574","phase":"PHASE4","title":"Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2000-01","conditions":"Anorexia Nervosa, Eating Disorders","enrollment":93},{"nctId":"NCT00466609","phase":"PHASE4","title":"Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2007-05","conditions":"Obsessive Compulsive Disorder","enrollment":54},{"nctId":"NCT02063425","phase":"NA","title":"\"Evaluation by Transcranial Magnetic Stimulation of the Benefit of Fluoxetine on Motor Recovery After Stroke\"","status":"TERMINATED","sponsor":"Centre Hospitalier St Anne","startDate":"2014-02","conditions":"Cerebral Infarction","enrollment":6},{"nctId":"NCT00849901","phase":"PHASE3","title":"A Study in the Treatment of Children and Adolescents With Major Depressive Disorder","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-03","conditions":"Major Depressive Disorder","enrollment":337},{"nctId":"NCT03051451","phase":"PHASE2","title":"Fixed Dose Combination of Fluoxetin and Metformin in the Management of Overweight and Obesity","status":"SUSPENDED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"","conditions":"Overweight and Obesity","enrollment":150},{"nctId":"NCT01838681","phase":"PHASE3","title":"Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2013-06","conditions":"Major Depressive Disorder","enrollment":1986},{"nctId":"NCT01136213","phase":"","title":"Investigation of the Serotoninergic System in Multiple System Atrophy: a Positron Emission Tomography (PET) Study","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2010-04","conditions":"Multiple System Atrophy","enrollment":53},{"nctId":"NCT03138681","phase":"PHASE2","title":"Rapid Antidepressant Effects of ATP and Phosphocreatine","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2017-05-03","conditions":"Major Depressive Disorder","enrollment":42},{"nctId":"NCT00339079","phase":"PHASE1, PHASE2","title":"Treatment of Hypochondriasis With CBT and/or SSRI","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2006-06","conditions":"Hypochondriasis","enrollment":195},{"nctId":"NCT02488538","phase":"PHASE3","title":"Combined Oral Contraceptives and Fluoxetine Versus Combined Oral Contraceptives in Severe Premenstrual Syndrome","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2015-07","conditions":"Premenstrual Syndrome","enrollment":300},{"nctId":"NCT00061113","phase":"PHASE4","title":"Substance Dependent Teens - Impact of Treating Depression Study 1 - 1","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2001-02","conditions":"Alcohol-Related Disorders, Marijuana Abuse, Substance-Related Disorders","enrollment":126},{"nctId":"NCT02934035","phase":"","title":"Early Improvement in Individual Symptoms and Response to Antidepressants in Patients With Major Depressive Disorder","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2016-09","conditions":"Major Depressive Disorder","enrollment":10000},{"nctId":"NCT02569970","phase":"PHASE3","title":"Efficacy of Fluoxetine Against Seizure-induced Central Apneas","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2010-11","conditions":"Epilepsy, Ictal/Post-ictal Hypoxemia","enrollment":70},{"nctId":"NCT02476136","phase":"","title":"Initial Severity and Antidepressant Efficacy for Anxiety Disorders: an Individual Patient Data Meta-analysis","status":"UNKNOWN","sponsor":"prof. Peter de Jonge","startDate":"2015-05","conditions":"Anxiety Disorders, Panic Disorder, Obsessive-compulsive Disorder","enrollment":8800},{"nctId":"NCT02562053","phase":"PHASE3","title":"Does Adding Oral Contraceptives to Fluoxetine Improve the Management of Premenstrual Syndrome?","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2015-10","conditions":"Premenstrual Syndrome","enrollment":300},{"nctId":"NCT00797966","phase":"PHASE2","title":"Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2009-05","conditions":"Major Depressive Disorder","enrollment":850},{"nctId":"NCT01674868","phase":"NA","title":"Fluoxetine for Motor, Aphasia, and Neglect Recovery After Ischemic Stroke","status":"WITHDRAWN","sponsor":"Spaulding Rehabilitation Hospital","startDate":"2013-04","conditions":"Stroke","enrollment":""},{"nctId":"NCT01808612","phase":"PHASE3","title":"A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term Dosing","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-03","conditions":"Major Depressive Disorder","enrollment":513},{"nctId":"NCT00129467","phase":"NA","title":"Methylphenidate for Depressed Cancer Patients Receiving Palliative Care","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2005-02","conditions":"Depression, Palliative Care, Cancer","enrollment":47},{"nctId":"NCT01146548","phase":"PHASE2","title":"Fluoxetine in Multiple System Atrophy Patients","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2008-05","conditions":"Multiple System Atrophy","enrollment":87},{"nctId":"NCT00027404","phase":"NA","title":"Study of Fluoxetine in Adults With Autistic Disorder","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2001-09","conditions":"Autistic Disorder","enrollment":48},{"nctId":"NCT00965562","phase":"NA","title":"Comparison of Fluoxetine, Calcium and Placebo for the Treatment of Moderate to Severe Premenstrual Syndrome (PMS)","status":"COMPLETED","sponsor":"Donaghue Medical Research Foundation","startDate":"2000-09","conditions":"Premenstrual Syndrome","enrollment":49},{"nctId":"NCT01963832","phase":"PHASE2","title":"RCT of a Neuroplasticity Agent and CI Therapy for Severe Arm Paresis After Stroke","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2016-11","conditions":"Severe Stroke With Affected Arm Motor Function","enrollment":""},{"nctId":"NCT00592670","phase":"NA","title":"Hypoglycemia Associated Autonomic Failure in Type 1 DM","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2005-03","conditions":"Type 1 Diabetes","enrollment":48},{"nctId":"NCT01635218","phase":"PHASE2","title":"Homeopathic Treatment for Depression in Peri- and Postmenopausal Women","status":"COMPLETED","sponsor":"Hospital Juarez de Mexico","startDate":"2012-03","conditions":"Moderate Depression, Menopausal and Postmenopausal Disorders","enrollment":133},{"nctId":"NCT01699490","phase":"PHASE4","title":"Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder","status":"UNKNOWN","sponsor":"National Cheng-Kung University Hospital","startDate":"2012-08","conditions":"Major Depressive Disorder","enrollment":200},{"nctId":"NCT01737541","phase":"PHASE3","title":"Fluoxetine for Motor Recovery After Acute Intracerebral Hemorrhage","status":"TERMINATED","sponsor":"Universidad Autónoma de Aguascalientes","startDate":"2012-11","conditions":"Intracerebral Hemorrhage, Motor Impairment","enrollment":32},{"nctId":"NCT01254305","phase":"PHASE2","title":"Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2011-04","conditions":"Major Depressive Disorder","enrollment":262},{"nctId":"NCT01185977","phase":"PHASE4","title":"Biomarkers of Antidepressant Treatment in Adolescents With Major Depression (The Adolescents MDD Study)","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2010-04","conditions":"Major Depressive Disorder","enrollment":26},{"nctId":"NCT00958204","phase":"PHASE3","title":"Light, Ion, and Fluoxetine Efficacy (LIFE) in Depression","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2009-10","conditions":"Major Depressive Disorder (MDD)","enrollment":134},{"nctId":"NCT00118404","phase":"PHASE3","title":"Cognitive Therapy for Recurrent Depression","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2000-03","conditions":"Depression","enrollment":523},{"nctId":"NCT00183339","phase":"PHASE2","title":"Early Intervention With Fluoxetine in Autism","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2005-07","conditions":"Autistic Disorder","enrollment":18},{"nctId":"NCT00000379","phase":"PHASE3","title":"Fluoxetine vs EMDR to Treat Post-Traumatic Stress Disorder (PTSD)","status":"COMPLETED","sponsor":"Boston University","startDate":"1999-01","conditions":"Stress Disorders, Post-Traumatic","enrollment":""},{"nctId":"NCT01569126","phase":"PHASE1","title":"A Study of LY110140 in Healthy Japanese Male Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-04","conditions":"Healthy Volunteer","enrollment":56},{"nctId":"NCT00000381","phase":"PHASE3","title":"Fluoxetine for Anxious Children","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"1997-06","conditions":"Anxiety Disorders","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":31,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"placebo + fluoxetine","genericName":"placebo + fluoxetine","companyName":"University of Florida","companyId":"university-of-florida","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fluoxetine selectively inhibits serotonin reuptake in the brain, increasing serotonin availability at synapses to improve mood and reduce depressive symptoms. Used for Major depressive disorder, Obsessive-compulsive disorder, Panic disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}